Chinese Biotech Companies Making Inroads in the Middle East: A Strategic Move

Frank Mei, a Life Sciences Partner and Head of Risk Consulting at KPMG China and ASPAC, emphasized the immense potential for Chinese biotech innovation in emerging markets worldwide. KPMG China's strategic initiative is to support these companies in establishing a strong international presence by providing assistance in crafting global strategies, developing sustainable business models, and fostering mutually beneficial collaborations within the biotech ecosystem. Frank Mei, a Life Sciences...

Frank Mei, a Life Sciences Partner and Head of Risk Consulting at KPMG China and ASPAC, emphasized the immense potential for Chinese biotech innovation in emerging markets worldwide. KPMG China's strategic initiative is to support these companies in establishing a strong international presence by providing assistance in crafting global strategies, developing sustainable business models, and fostering mutually beneficial collaborations within the biotech ecosystem.

While the Middle East offers promising prospects, Chinese enterprises venturing into the region must address challenges related to regulatory systems, market structures, and cultural integration. Leveraging its expertise and global network, KPMG China is actively promoting biotech innovation systems in China, the Middle East, and other emerging markets, contributing to advancements in the fields of innovation and healthcare.

This conference serves as a pivotal step in KPMG China's ongoing efforts to facilitate the expansion of biotech innovators into emerging markets worldwide. Going forward, KPMG China will continue exploring opportunities for local biotech companies to venture into other burgeoning regions, including the ASEAN region and South America.

View original content:https://www.prnewswire.co.uk/news-releases/chinese-biotech-companies-making-inroads-in-the-middle-east-a-strategic-move-301848110.html